Search

Displaying results 2301 - 2310 of 7687 in total
  1. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. … High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.

  2. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).

  3. Drug

    Levothyroxine

    go.drugbank.com/drugs/DB00451
    ApprovedInvestigational

    However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. … This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according

  4. Drug

    Fluasterone

    go.drugbank.com/drugs/DB06250
    Experimental

    Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

  5. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again.

  6. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes

  7. Drug

    Indomethacin

    go.drugbank.com/drugs/DB00328
    ApprovedInvestigational

    superficial punctate keratitis and subjective symptoms of discomfort, including pain, burning or pricking, or a tingling sensation after instillation into the cul‐de‐sac. … NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole

    International brands: Nu-IndoProducts: Nu-indo Cap 25mg, Nu-indo Cap 50mg
  8. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    It is an oxidation product of adrenaline which enhances the microcirculatory tone [A19747]. … It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.

    International brands: Di Ka Ning, Le Ka Ning
  9. Drug

    Tedizolid phosphate

    go.drugbank.com/drugs/DB09042
    Approved

    [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). … This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232]

  10. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    Additional experiments suggest that FM-VP4 can reduce plasma LDL cholesterol levels and triglyceride levels, reduce weight gain and exert a anti-atherosclerosis effect.